Shattuck Labs, Inc.
STTK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for STTK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · STTK
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing bispecific antibody therapeutics, with lead candidate SL-325 in Phase 2 for Crohn's disease and a pipeline including SL-846 and other DR3-based programs.
Key risk: Clinical development risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$706.6M
Cash Runway
31.9 moLead Asset
sl-172154 (Phase 1)Next Catalyst
Phase2_Topline · Sep 30, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 5 clinical trials · 3 catalysts for Shattuck Labs, Inc..
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing bispecific antibody therapeutics, with lead candidate SL-325 in Phase 2 for Crohn's disease and a pipeline including SL-846 and other DR3-based programs.
- Lead product candidate SL-325 is in Phase 2 clinical development for Crohn's disease [sec_mda · as of 2026-08-11].
- Cash and equivalents of $63.3M as of 2026-06-30, with an accumulated deficit of $460.4M as of June 30, 2026 [sec_mda · as of 2026-08-11].
- Net loss of $15.2M for the quarter ended June 30, 2026 [latest reported financials].
- Pipeline includes SL-846, a planned Phase 1 candidate, and other DR3-based bispecific antibodies [sec_mda · as of 2026-08-11].
- The company has not been profitable since inception and expects to continue incurring significant operating losses [sec_mda · as of 2026-08-11].
What works
- SL-325 has advanced to Phase 2 in Crohn's disease, indicating clinical progress [sec_mda · as of 2026-08-11].
- The company has a cash position of $63.3M as of 2026-06-30, providing near-term operational runway [latest reported financials].
- Pipeline includes multiple DR3-based bispecific candidates and a novel TRIM7 inhibitor program, diversifying therapeutic approaches [sec_mda · as of 2024-11-14].
What to weigh
- The company has never been profitable and carries a substantial accumulated deficit of $460.4M as of June 30, 2026 [sec_mda · as of 2026-08-11].
- SL-325 is still in early-to-mid stage clinical development, with no approved products or revenue [latest reported financials].
- Operating losses are expected to increase as the company initiates additional clinical trials for SL-325 and SL-846 [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
SL-325 is in Phase 2 for Crohn's disease
“initiate and advance through Phase 2 clinical development for our lead product candidate, SL-325, in Crohn's disease”
SEC MD&A · August 11, 2026
Accumulated deficit of $460.4M as of June 30, 2026
“as of June 30, 2026, we had an accumulated deficit of $460.4 million”
SEC MD&A · August 11, 2026
SL-846 is a planned Phase 1 candidate
“initiate nonclinical studies and clinical trials for SL-846, including our planned Phase 1 clinical trial”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2026-09-30 · Phase2_Topline · sl-325 — Phase 2 Readout: sl-325 — Topline results from the Phase 2 trial of SL-325 in Crohn's disease are expected, which will inform the drug's efficacy and safety profile.
- 2026-10-01 · Phase2_Start — Phase 2 Start: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of — Initiation of a new Phase 2 randomized, double-blind, placebo-controlled study for SL-325, expanding the clinical program.
- 2028-06-30 · Phase2_Topline · sl-325 — Phase 2 Readout: sl-325 — A subsequent Phase 2 readout for SL-325 is scheduled, providing longer-term efficacy and safety data.
Risks & what to watch (3)›
Key risks
- Clinical development risk — SL-325 and other candidates may fail in clinical trials, leading to significant losses [sec_mda · as of 2026-08-11].
- Financial sustainability — With no revenue and a $460.4M deficit, the company may need additional financing to fund operations [sec_mda · as of 2026-08-11].
- Regulatory and competitive risk — The biotech sector is highly competitive, and regulatory hurdles may delay or prevent product approvals [sec_mda · as of 2026-08-11].
What to watch
- Phase 2 topline data for SL-325 in Crohn's disease expected around 2026-09-30 [upcoming catalysts].
- Initiation of a Phase 2 randomized, double-blind, placebo-controlled study for SL-325 around 2026-10-01 [upcoming catalysts].
- Progress of SL-846 toward a Phase 1 clinical trial [sec_mda · as of 2026-08-11].
- Cash runway and potential need for additional financing given ongoing operating losses [sec_mda · as of 2026-08-11].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Shattuck Labs, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Shattuck Labs, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
31.9 months
D/E 0.05 · 0% dilution
Lead: Phase 2
3 candidates
3 upcoming, next in ~31d
5 buys · 6 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 2.0%
- Days to cover
- 1.9
- Shares short
- 1,466,321
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
STTK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Shattuck Labs, Inc.?
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing bispecific antibody therapeutics, with lead candidate SL-325 in Phase 2 for Crohn's disease and a pipeline including SL-846 and other DR3-based programs.
What is Shattuck Labs, Inc.'s lead drug candidate?
Shattuck Labs, Inc.'s most advanced tracked candidate is sl-172154 (Phase 1) for Acute Myeloid Leukemia.
What is Shattuck Labs, Inc.'s next catalyst?
Shattuck Labs, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: sl-325" — expected September 30, 2026.
Who is the CEO of Shattuck Labs, Inc.?
Dr. Taylor H. Schreiber M.D., Ph.D. is the chief executive officer of Shattuck Labs, Inc. (STTK).
Where is Shattuck Labs, Inc. headquartered?
Shattuck Labs, Inc. (STTK) is headquartered in Austin, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.